Henney Nominated for FDA Commissioner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

WASHINGTON--President Clinton has nominated Jane E. Henney, MD, vice president for health sciences, University of New Mexico, as the new FDA Commissioner. She would replace David M. Kessler, MD, who resigned more than a year ago and is now dean of the Yale University School of Medicine.

Dr. Henney, a cancer specialist, has served in government under every president since Jimmy Carter. She was the FDA’s deputy commissioner for operations from 1992 to 1994.

Her nomination won warm praise from many in the medical and public health fields, including Health and Human Services Secretary Donna E. Shalala, PhD. The Secretary called Dr. Henney "a talented manager" with "the solid medical and academic credentials that are needed to understand the burgeoning field of biomedical research."

However, several conservative Republicans have indicated their opposition to Dr. Henney. They want to know specifically if she had anything to do with the FDA’s decision to allow testing of the abortion drug RU-486.

Recent Videos
6 experts are featured in this series.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
6 experts are featured in this series.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content